PDS Biotechnology (PDSB) will announce quarterly earnings on Wednesday

PDS Biotechnology (NASDAQ: PDSB) Publishes Earnings Results, Lacks Estimates of $ 0.09 EPS

PDS Biotechnology (NASDAQ: PDSB – Get Rating) released its quarterly earnings results Wednesday. The company reported ($ 0.32) earnings per share for the quarter, missing analyst consensus estimates of ($ 0.23) by ($ 0.09), MarketWatch earnings reports. During the same quarter last year, the company reported earnings per share ($ 0.14).

Shares of PDSB were up $ 0.73 during Friday’s midday trading, reaching $ 4.56. 552,690 shares of the stock were traded, against an average volume of 232,316. PDS Biotechnology has a 12-month low of $ 3.47 and a 12-month high of $ 17.85. The company has a 50-day simple moving average of $ 5.66 and a 200-day simple moving average of $ 7.26.

Several institutional investors and hedge funds have recently bought and sold shares of PDSB. Morgan Stanley increased its stake in PDS Biotechnology by 2,254.9% during Q2. Morgan Stanley now owns 65,703 shares in the company worth $ 825,000 after purchasing an additional 62,913 shares in the last quarter. Goldman Sachs Group Inc. acquired a new equity interest in PDS Biotechnology during the third quarter for approximately $ 170,000. UBS Group AG purchased a new equity position in PDS Biotechnology in Q3 worth approximately $ 44,000. Northern Trust Corp increased its stake in PDS Biotechnology by 6.3% in Q4. Northern Trust Corp now owns 41,820 shares in the company worth $ 339,000 after acquiring an additional 2,466 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in PDS Biotechnology shares by 7,093.1% in Q4. Bank of America Corp DE now owns 4,172 shares in the company worth $ 34,000 after acquiring another 4,114 shares in the last quarter. 20.94% of the stock is held by institutional investors.

A number of research firms have recently weighed in on PDSB. Noble Financial reiterated a “buy” rating and issued a $ 22.00 price target on shares of PDS Biotechnology in a research report Thursday. StockNews.com updated PDS Biotechnology to a “selling” score in a research report on Saturday, April 9. Zacks Investment Research downgraded PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Friday. Finally, Alliance Global Partners reduced its PDS biotech price target from $ 18.00 to $ 16.00 in a research report on Friday. Two equity research analysts rated the stock with a sell rating and six assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, PDS Biotechnology currently has a consensus rating of “Buy” and an average price target of $ 17.00.

Information on PDS biotechnology (Get evaluation)

PDS Biotechnology Corporation, a clinical stage biopharmaceutical company, focuses on the development of multifunctional anticancer immunotherapies. Its flagship product is PDS0101 (HPV16), which is in a Phase II clinical trial providing first-line treatment for recurrent / metastatic head and neck cancer, human papillomavirus-associated malignancies, and cancer of the cervix.

Featured articles

Earnings History for PDS Biotechnology (NASDAQ: PDSB)

Receive news and assessments for PDS biotechnology every day – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Biotech PDS and related companies with MarketBeat.com’s FREE daily newsletter.


Leave a Comment

Your email address will not be published.